BRIEF-Navidea reports Q1 loss per share of $0.02 By: Reuters: Company News May 17, 2016 at 07:19 AM EDT * Expects to begin grant-funded phase 1/2 evaluation of lymphoseek - iv in kaposi's sarcoma patients in second half of 2016 Read More >> Related Stocks: Navidea Biopharmaceuticals Inc